English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

A single-nucleotide polymorphism (SNP) in the promoter region ofMDM2, SNP 309, is associated with hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus infection. The effect ofp53codon 72 polymorphism Arg72Pro on HCC risk remains inconsistent. This study evaluated the association ofMDM2andp53polymorphisms with the presence and early onset of HCC in Korean patients with chronic hepatitis B virus (HBV) infection. In total, 583 consecutive patients with chronic HBV infection were classified according to the presence (n = 287) or absence (n = 296) of HCC. TheMDM2SNP 309 andp53Arg72Pro were genotyped using restriction fragment length polymorphism method. TheMDM2G/G andp53Pro/Pro genotypes were more frequent in HCC group than in non-HCC group (P &lt; 0.001 andP = 0.004, respectively). Multivariate analysis for the presence of HCC revealed that the odds ratio (OR) forMDM2G/G over T/T was 4.89 (P &lt; 0.001) and that ofp53Pro/Pro over Arg/Arg was 3.03 (P = 0.006). CombinedMDM2G/G andp53Pro/Pro had a synergistic effect on HCC risk, with an OR of 20.78 (P &lt; 0.001). The mean age of tumor onset in patients withMDM2G/G genotype was 50.9 years compared with 55.1 with T/T genotype (P = 0.018) and that withp53Pro/Pro was 49.7 years compared with 52.9 with Arg/Arg (P = 0.040). Thus,MDM2SNP 309 andp53Arg72Pro are associated with the early development of HCC in Korean patients with chronic HBV infection.

carcinogenesis

MDM2               and               p53               polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection